Clinical Trial: Safety, Tolerability, and Efficacy of Oral KM-023 in Adult Patients With Pachyonychia Congenita (pEDD-PC)

U.S., Oct. 27 -- ClinicalTrials.gov registry received information related to the study (NCT07893483) titled 'Safety, Tolerability, and Efficacy of Oral KM-023 in Adult Patients With Pachyonychia Congenita (pEDD-PC)' on Sept. 06.

Brief Summary: The goal of this clinical trial is to learn if KM-023 is safe and well tolerated in adults with Pachyonychia Congenita (PC). The study will also explore whether KM-023 may help reduce pain, improve mobility, and lessen the impact of PC on participants' daily lives.

The main questions it aims to answer are:

What medical problems or side effects do participants experience when taking KM-023? Does KM-023 improve participants' ability to walk and perform physical activities? Does KM-023 reduce pain, es...